Cullinan Therapeutics Quarterly Balance Sheet
NASDAQ: CGEMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cullinan Therapeutics financial position
As of Jun 30, 2026, Cullinan Therapeutics reported total assets of $363.8 million, down 30.1% from a year earlier against total liabilities of $42.0 million. Shareholders' equity stood at $321.8 million, or 88.4% of assets. The company held $78.6 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 8.42, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Cullinan Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 78.64M | 75.08M | 88.33M | 103.33M | 72.82M | 76.66M | 83.00M | 102.08M | 115.02M | 74.23M | 98.43M | 64.85M |
| Short-Term Investments | 255.90M | 276.80M | 289.56M | 229.26M | 192.66M | 227.17M | 315.97M | 475.99M | 547.47M | 358.78M | 368.63M | 401.58M |
| Total Current Assets | 341.97M | 361.41M | 386.76M | 342.24M | 275.91M | 317.77M | 414.67M | 592.04M | 677.80M | 445.72M | 480.19M | 476.71M |
| Property, Plant & Equipment | 263.00K | 342.00K | 421.00K | 489.00K | 569.00K | 607.00K | 683.00K | 760.00K | 836.00K | 913.00K | 989.00K | 1.07M |
| Long-Term Investments | 19.02M | 38.50M | 58.27M | 140.00M | 242.30M | 259.39M | 204.44M | 57.98M | — | — | 0 | 13.54M |
| Total Assets | 363.79M | 402.98M | 448.37M | 484.13M | 520.33M | 579.68M | 621.82M | 653.25M | 681.22M | 449.43M | 484.18M | 494.71M |
| Accounts Payable | 3.73M | 2.51M | 841.00K | 1.72M | 2.46M | 3.40M | 1.68M | 2.12M | 1.55M | 3.71M | 2.49M | 951.00K |
| Total Current Liabilities | 40.63M | 35.15M | 37.74M | 32.76M | 28.06M | 27.35M | 30.65M | 24.20M | 23.48M | 21.93M | 28.14M | 23.44M |
| Total Liabilities | 42.03M | 36.81M | 39.64M | 32.76M | 28.18M | 27.84M | 31.50M | 25.39M | 25.00M | 23.77M | 30.29M | 25.89M |
| Shareholders' Equity | 321.75M | 366.17M | 408.73M | 451.37M | 492.15M | 551.84M | 590.33M | 627.86M | 656.22M | 425.67M | 453.70M | 468.82M |
| Retained Earnings | -691.48M | -637.78M | -588.12M | -537.41M | -486.80M | -416.74M | -368.24M | -320.59M | -280.03M | -238.00M | -200.86M | -177.05M |
| Net Cash (Debt) | 334.54M | 351.88M | 377.90M | 332.60M | 265.48M | 303.83M | 398.98M | 578.08M | 662.50M | 433.01M | 467.07M | 466.43M |
| Shares Outstanding | 64.35M | 61.45M | 60.24M | 59.08M | 59.07M | 58.70M | 58.51M | 58.14M | 57.87M | 43.07M | 42.90M | 42.76M |
This table shows 12 quarterly periods of Cullinan Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 13 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow CGEM's reporting calendar. What is a balance sheet?